Pos1495-HPR Empowering Health Professionals Participation in Cannabis & Hemp Data Collection Through the Budsinfo™ Cerium™ Education Platforms

Background: Cannabis and its derivatives are increasingly being considered as potential adjunct treatments for rheumatic diseases [1]. However, there is a significant lack of evidence and data collection regarding their use and impact within the rheumatic disease community. As the prevalence and diversity of cannabinoid-containing products rises globally, the task of gathering useful Real-World Data (RWD) becomes increasingly complex. National Institute on Drug Abuse (NIDA) has expressed the urgent need for harmonizing data collection to meet this challenge [2]. Compounding this issue, Health Care Professionals (HCPs) are often hesitant to record Cannabis use data in patient files in countries where there are perceived legal challenges associated with documenting its use. The combination of a dearth of systematic learning and documentation hinders a comprehensive understanding of the benefits, risks, and potential drug-drug interactions (DDIs) associated with these products. Addressing this gap is crucial for informed healthcare decisions in the context of rheumatic disease management. Objectives: To improve HCPs knowledge, attitudes (K/A), and data collection practices related to Cannabis and Cannabis-derived products (CCDP); definition includes hemp and hemp-derived products. Methods: We conducted a preliminary survey with HCPs, evaluating K/A of CCDPs. K/A survey is 40 questions in length. Building on the insights gained, we developed a pilot study that includes an updated K/A survey with an educational platform, known as CeriumTM. The study utilized qualitative methods to gather feedback on the content and delivery of the educational material. We designed four distinct modules for the pilot educational program. The CeriumTM program incorporates interactive elements such as blogs, a virtual journal club, and opportunities to discuss patient-reported outcome (PRO) measures one-on-one. A systematic data collection tool, BudsinfoTM, was integrated into the program to report and analyze real-time outcomes related to CCDP use from the participating HCPs. Results: At the time of submission our survey and educational intervention is ongoing. To date, 63% support the use of an experience (i.e., adverse event (AE)) reporting tool. 16% report being confident in their current knowledge of cannabinoid molecules. News and social media are the most common source to obtain information for cannabis; lectures and medical journals for other new medications. Of the AE reported, 30% report having arthritis as a comorbid condition. Data collection continues and is expected to be complete by May 2024. Preliminary data and analysis will be shared regarding the pre- and post-completed survey results. Conclusion: BudsinfoTM and CeriumTM constitute a potentially comprehensive solution to bridge critical gaps in AE reporting and promote data-driven decision-making for regulatory agencies, HCPs, and the public. This holistic approach of providing education and data collection tools contributes to enhanced product safety understanding and consumer health in rapidly evolving markets, fostering a more informed and responsive public health ecosystem. We believe this is the first attempt at providing an intervention that addresses both CCDP data collection and education. REFERENCES: [1] Marcu, J., Simon, T. A. & Molloy, P. A New Ache in The World of Joints. Arch. Rheumatol. Arthritis Res. (2021). [2] Weiss, S. R. B. & Volkow, N. D. Coordinating cannabis data collection globally: Policy implications. Addiction117, 1520–1521 (2022). Acknowledgements: NIL. Disclosure of Interests: Jahan Marcu: None declared, Philip Molloy: None declared, Matthew Wabwire: None declared, Shannon Heaning: None declared, Kayla Pray: None declared, Teresa A. Simon Bristol Myers Squibb, Merck, Bristol Myers Squibb, Bristol Myers Squibb and Janssen Pharmaceuticals.